← Browse by Condition
Medical Condition
solid tumor
Total Trials
48
Recruiting Now
48
Trial Phases
Phase 1, Phase 1, Phase 2, EARLY_Phase 1
NCT06609187 Phase 1
Recruiting
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Enrollment
20 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
NCT04196257 Phase 1
Recruiting
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
Enrollment
50 pts
Location
United States
Sponsor
Bio-Path Holdings, Inc.
NCT07229586 Phase 1, Phase 2
Recruiting
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Enrollment
100 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica...
NCT06249256 EARLY_Phase 1
Recruiting
An Exploratory Study on the Treatment of Advanced Solid Tumors by Fast CAR T Cells
Enrollment
12 pts
Location
China
Sponsor
Shanghai Cell Therapy Group Co...
NCT04386967 Phase 1, Phase 2
Recruiting
OH2 Injection in Solid Tumors
Enrollment
30 pts
Location
China
Sponsor
Binhui Biopharmaceutical Co., ...
NCT05661201 Phase 1
Recruiting
NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors
Enrollment
24 pts
Location
United States
Sponsor
Georgetown University
NCT04300556 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Enrollment
182 pts
Location
United States, Franc...
Sponsor
Eisai Inc.
NCT05076760 Phase 1
Recruiting
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Enrollment
40 pts
Location
United States
Sponsor
Memgen, Inc.
NCT05828459 Phase 1
Recruiting
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
Enrollment
150 pts
Location
France
Sponsor
Onward Therapeutics
NCT06394622 Phase 1
Recruiting
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
Enrollment
12 pts
Location
China
Sponsor
Fudan University
NCT06014502 Phase 1
Recruiting
Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors
Enrollment
105 pts
Location
United States
Sponsor
ImmunoGenesis
NCT06441331 Phase 1
Recruiting
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Enrollment
20 pts
Location
United States, Spain
Sponsor
ITM Solucin GmbH
NCT06954077 Phase 1
Recruiting
A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Enrollment
45 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
NCT05985161 Phase 2
Recruiting
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
Enrollment
45 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT06712680 Phase 1, Phase 2
Recruiting
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
Enrollment
115 pts
Location
China
Sponsor
Sichuan Huiyu Pharmaceutical C...
NCT06440005 Phase 1
Recruiting
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Enrollment
80 pts
Location
United States
Sponsor
Angiex, Inc.
NCT06801002 Phase 1
Recruiting
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Enrollment
25 pts
Location
United States
Sponsor
Jabez Bioscience, Inc
NCT07382531 Phase 1, Phase 2
Recruiting
OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors
Enrollment
30 pts
Location
China
Sponsor
Binhui Biopharmaceutical Co., ...
NCT06526819 Phase 1, Phase 2
Recruiting
SMP-3124LP in Adults With Advanced Solid Tumors
Enrollment
120 pts
Location
United States, Japan
Sponsor
Sumitomo Pharma America, Inc.
NCT03891706 Phase 1
Recruiting
Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors
Enrollment
30 pts
Location
China
Sponsor
Guangzhou FineImmune Biotechno...
NCT06645808 EARLY_Phase 1
Recruiting
PET-imaging of Two Vartumabs in Patients With Solid Tumors
Enrollment
32 pts
Location
Netherlands
Sponsor
Var2 Pharmaceuticals
NCT05707325 EARLY_Phase 1
Recruiting
Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies
Enrollment
30 pts
Location
China
Sponsor
Westlake Therapeutics
NCT06101082 Phase 1
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
Enrollment
9 pts
Location
China
Sponsor
China Medical University, Chin...
NCT05923008 Phase 1, Phase 2
Recruiting
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Enrollment
182 pts
Location
Australia
Sponsor
Innovent Biologics (Suzhou) Co...
NCT06873659 Phase 1
Recruiting
SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Enrollment
96 pts
Location
China
Sponsor
Qurgen Inc.
NCT06739395 Phase 2
Recruiting
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Enrollment
300 pts
Location
China
Sponsor
Tianjin Medical University Sec...
NCT06549946 Phase 1, Phase 2
Recruiting
Ixovex-1 Single Agent and Combination Therapy
Enrollment
18 pts
Location
United Kingdom
Sponsor
Psivac Ltd
NCT03611595 Phase 1
Recruiting
Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
Enrollment
18 pts
Location
United States
Sponsor
Peter Zage
NCT03991832 Phase 2
Recruiting
Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors
Enrollment
58 pts
Location
Canada
Sponsor
University Health Network, Tor...
NCT05306509
Recruiting
Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology
Enrollment
120 pts
Location
China
Sponsor
Children's Hospital of Fudan U...
NCT07137312
Recruiting
Ex Vivo Expansion (ACT-X)
Enrollment
24 pts
Location
United States
Sponsor
Mayo Clinic
NCT05244551 Phase 1
Recruiting
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors
Enrollment
85 pts
Location
United States, China
Sponsor
Abbisko Therapeutics Co, Ltd
NCT04794972 Phase 1
Recruiting
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Enrollment
60 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
NCT06342336 Phase 1
Recruiting
HS-IT101 Injection in the Treatment of Advanced Solid Tumors
Enrollment
44 pts
Location
China
Sponsor
Qingdao Sino-Cell Biomedicine ...
NCT07392736 Phase 1, Phase 2
Recruiting
A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors.
Enrollment
228 pts
Location
China
Sponsor
Advenchen Laboratories, LLC
NCT06810544 Phase 1, Phase 2
Recruiting
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Enrollment
191 pts
Location
United States
Sponsor
Tango Therapeutics, Inc.
NCT06212076 Phase 1, Phase 2
Recruiting
Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
Enrollment
60 pts
Location
China
Sponsor
Nanjing Immunophage Biotech Co...
NCT05390827
Recruiting
Remote Digital Physiologic Data Collection in Cancer: An MSK Registry Protocol
Enrollment
3,644 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT06503783 Phase 1
Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
Enrollment
20 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
NCT03739827
Recruiting
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
Enrollment
10,000 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
NCT06234423 Phase 1
Recruiting
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Enrollment
263 pts
Location
United States, Austr...
Sponsor
OnCusp Therapeutics, Inc.
NCT05831033 EARLY_Phase 1
Recruiting
Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced Solid Tumors
Enrollment
16 pts
Location
China
Sponsor
Shanghai General Hospital, Sha...
NCT05269316 Phase 1, Phase 2
Recruiting
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Enrollment
61 pts
Location
United States, Austr...
Sponsor
Impact Therapeutics, Inc.
NCT06248697 EARLY_Phase 1
Recruiting
Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors
Enrollment
16 pts
Location
China
Sponsor
Shanghai Cell Therapy Group Co...
NCT06956248
Recruiting
Innovating Access to Novel Therapies Through Standardized Prospective Integration of Response Evaluations (IMPACT-INSPIRE)
Enrollment
50 pts
Location
Singapore
Sponsor
National Cancer Centre, Singap...
NCT02992210 Phase 1, Phase 2
Recruiting
Study on GD2 Positive Solid Tumors by 4SCAR-GD2
Enrollment
100 pts
Location
China
Sponsor
Shenzhen Geno-Immune Medical I...
NCT05645523 EARLY_Phase 1
Recruiting
Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors
Enrollment
25 pts
Location
United States
Sponsor
St. Jude Children's Research H...
NCT06307249 Phase 1
Recruiting
Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
Enrollment
50 pts
Location
Lebanon
Sponsor
Lebanese University